ImmuPharma (LON:IMM) Trading Up 23.8% – Should You Buy?

Shares of ImmuPharma plc (LON:IMMGet Free Report) shot up 23.8% during mid-day trading on Friday . The company traded as high as GBX 5.70 ($0.07) and last traded at GBX 4.83 ($0.06). 16,731,404 shares changed hands during mid-day trading, a decline of 23% from the average session volume of 21,725,510 shares. The stock had previously closed at GBX 3.90 ($0.05).

ImmuPharma Stock Up 23.8 %

The company’s fifty day moving average is GBX 2.39 and its two-hundred day moving average is GBX 1.93. The stock has a market cap of £20.11 million, a price-to-earnings ratio of -483.00 and a beta of 1.53.

About ImmuPharma

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Featured Articles

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.